Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | BCL2 | P10415 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320873 | 0.86 | MCL1 (0.32) | BCL2MCL1 | |
| SCHEMBL2841737 | 0.71 | HTR6 (0.36) | KDM4E | |
| SCHEMBL3837631 | 0.71 | KDM4E (0.34) | KDM4EMAPT | |
| SCHEMBL3872426 | 0.69 | HTR1A (0.32) | — | |
| SCHEMBL975060 | 0.67 | GPR3 (0.44) | KDM4EMAPT | |
| SCHEMBL3483349 | 0.65 | KDM4E (0.42) | BCL2MCL1KDM4E | |
| SCHEMBL3341086 | 0.64 | SMN1; SMN2 (0.32) | KDM4E | |
| SCHEMBL2931203 | 0.64 | KDM4E (0.38) | CHRNB2CHRNA4KDM4E | |
| SCHEMBL3483473 | 0.64 | KDM4E (0.33) | KDM4E | |
| SCHEMBL3339082 | 0.62 | KDM4E (0.43) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120886-A1 | ARYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | claimed |
| EP-1953141-A1 | Aryl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-06 | — | — | EP | claimed |
| US-20100120886-A1 | ARYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| EP-1953141-A1 | Aryl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120886-A1 | ARYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | HTR6, HTR2A, HTR2C | CHRNB2 676/4885CHRNA7 588/4885CHRNA4 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.